• Lisa J McGarry, Sanjay Merchant, Dilip Nathwani, Vivek Pawar, Kelly DeLong, David Thompson, Kasem Akhras, Michael Ingham, and Milton C Weinstein.
• i3 Innovus, 10 Cabot Road, Medford, MA 02155, USA.
• J Med Econ. 2010 Mar 1;13(1):142-7.

BackgroundVentilator-associated pneumonia (VAP), the most common nosocomial infection in critically ill patients, is associated with significantly longer duration of mechanical ventilation, and increased mortality, hospital days, and health-care costs. A previously published prospective, randomized study established the noninferiority of intravenous (IV) doripenem versus IV imipenem/cilastatin ('imipenem') for VAP. This study compares the economic outcomes of IV therapy with doripenem versus imipenem as first-line treatment for VAP.MethodsA decision-analytic model of inpatient care and outcomes for VAP was used to estimate costs associated with VAP treatment. The model calculates total hospital costs, comprising costs of initial and concomitant therapy, and costs associated with mechanical ventilation, intensive care unit stays, and total days in hospital.ResultsTotal treatment costs for doripenem were $10,630 lower than for imipenem ($71,259 vs. 81,889), driven primarily by differences in costs of mechanical ventilation ($45,224 for doripenem, $57,348 for imipenem). Probabilistic sensitivity analyses found doripenem consistently cost saving versus imipenem in 1,000 simulations. Study limitations include use of a simple model to represent a complex disease process and reliance on trial data that may not reflect real-world care and outcomes.ConclusionsDoripenem is a cost saving first-line treatment for VAP versus imipenem while providing an equivalent rate of cure.

37 keywords...

hide…